Result of GM and TVR

RNS Number : 8036Q

AorTech International PLC

08 June 2018

 

8 June 2018

AorTech International plc

("AorTech" or the "Company")

Result of General Meeting

and

Total Voting Rights

AorTech International plc (AIM: AOR), the biomaterials and medical device IP company, announces that all resolutions put to Shareholders at the General Meeting held earlier today were duly passed.

Application has therefore been made for, in aggregate, 9,128,913 new Ordinary Shares to be admitted to trading on AIM comprising 5,740,267 Placing Shares, 1,260,004 Subscription Shares, 461,333 Consideration Shares and 1,667,309 Open Offer Shares. Admission is expected to occur at 8.00 am on 11 June 2018.

Following Admission, the Company will have 14,686,608 Ordinary Shares in issue admitted to trading on AIM. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement should be read in conjunction with the full text of the Circular which was posted to Shareholders on 22 May 2018, copies of which are available on the Company's website at www.aortech.net.  Capitalised terms in this announcement have the same meaning as given in the Circular.

This announcement includes inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

For further information contact:

AorTech International plc                                            Tel: [phone] 

Bill Brown, Chairman                                                                                     

Stockdale Securities Limited                                       Tel: [phone] 

Tom Griffiths/David Coaten                                                       

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA.  With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

 

END

 

 

MSCKMGGVGRLGRZM